Marginal Bone Level Around Titanium Implants Produced by Additive Manufacture

Sponsor
University of Sao Paulo (Other)
Overall Status
Recruiting
CT.gov ID
NCT05627037
Collaborator
Plenum (M3 Health Industria e Comercio de Produtos Médicos) (Other)
75
1
2
19
3.9

Study Details

Study Description

Brief Summary

The aim of this study will be to evaluate the non-inferiority of implants produced by additive manufacture loaded in 30 days when compared with those loaded in 90 days, in relation to marginal bone loss, after 01 (one) year of follow-up

Condition or Disease Intervention/Treatment Phase
  • Device: Dental implant produced by additive manufacture
  • Device: Dental implant produced by additive manufacture
N/A

Detailed Description

This randomized Split-mouth clinical study of non-inferiority will monitor for one year partially edentulous patients in the posterior region of the mandible or maxilla, rehabilitated with 2 implants (AM) in the same Arch to evaluate the success rate of the implant, one loaded at 30 days after installation and the other at 90 days. Changes in marginal bone level and osseointegration success will be evaluated, with visits and data collection in 0 days (baseline), 30 days, 90 days, 6 months and 1 year

Study Design

Study Type:
Interventional
Anticipated Enrollment :
75 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Split-Mouth Study ModelSplit-Mouth Study Model
Masking:
Double (Care Provider, Outcomes Assessor)
Masking Description:
either the operator or the patient will be blinded for the primary outcome
Primary Purpose:
Treatment
Official Title:
Evaluation of the Marginal Bone Level of Titanium Implants Produced by Additive Manufacture, in 30 and 90 Days: Randomized Within-subject Clinical Trial of 1-year Non-inferiority
Anticipated Study Start Date :
Nov 1, 2022
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jun 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Loading in 30 days

Implant allocated to the study arm will be restored with a temporary restoration after 30 days of implant placement, that will be replaced with definitive restoration after 90 days of implant placement.

Device: Dental implant produced by additive manufacture
In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will be randomly allocated to receive Temporary restoration after 30 days and definitive restoration after 90 days

Active Comparator: Loading in 90 days

Implant allocated to the study arm will be restored directly with the definitive restoration after 90 days of implant placement.

Device: Dental implant produced by additive manufacture
In a split-mouth setup, each participant will receive two implants in the posterior region of the mandible or maxilla. After implant insertion, one implant will receive definitive restoration after 90 days

Outcome Measures

Primary Outcome Measures

  1. Marginal Bone Loss (MBL) [1 year]

    Digital periapical radiographs will be taken at the implant installation (baseline) after 1 year. The radiographs will be taken using the parallelism technique with a positioner that supports the digital sensor in order to standardize the radiographs.

Secondary Outcome Measures

  1. Implant success rate [1 year]

    The success rate or failure of each implant in clinical and radiographic findings will be classified using the success criteria defined by Buser et al. (1990) Absence of persistent subjective complaints, such as pain, foreign body sensation and/or dysesthesia. Absence of a recurrent peri-implant infection with suppuration. Absence of mobility. Absence of a continuous radiolucency around the implant. Possibility for restoration. These criteria will be monitored at 0 days (baseline), 30 days, 90 days, 6 months, and the final endpoint is one year

  2. Modified Plaque Index (mPI) [1 year]

    Modified Plaque Index (Mombelli, Van Oosten Et.Al 1987): Scoring Criteria: Score 0: No detection of plaque Score 1:Plaque only recognized by running a probe across the smooth marginal surface of the implant Score 2: Plaque can be seen by the naked eye. Score 3: Abundance of soft matter. The changes in Modified Plaque Index (mPI) will be monitored at 0 days (baseline), 30 days, 90 days, 6 months, and the final endpoint is one year

  3. Modified Bleeding Index (mBI) [1 year]

    Modified Sulcus Bleeding Index (Mombelli, Van Oosten Et.Al 1987): Scoring Criteria: Score 0: No bleeding when probe is passed along the gingival margin. Score 1: Isolated bleeding, spots present. Score 2: Blood forms a confluent red line on margins. Score 3: Heavy or profuse bleeding. The changes in Modified Bleeding Index (mBI) will be monitored by a blinded calibrated examiner at 0 days (baseline), 30 days, 90 days, 6 months, and the final endpoint is one year

  4. Pocket probing depth (PPD) [1 year]

    Pocket Probing Depth (PPD) will be measured by a blinded calibrated Examiner, and The changes in Pocket Probing Depth (PPD) will be monitored at 0 days (baseline), 30 days, 90 days, 6 months, and the final endpoint is one year

  5. clinical attachment level (CAL) [1 year]

    Clinical attachment level (CAL) will be measured by a blinded calibrated Examiner, and The changes in clinical attachment level (CAL) will be monitored at 0 days (baseline), 30 days, 90 days, 6 months, and the final endpoint is one year

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Patients treated and referred by the Dental Clinic of the School of Dentistry of the University of São Paulo;

  • Individuals over 18 years and under 70 years of age;

  • Good general health;

  • signed Informed Consent Form;

  • Need for rehabilitation with dental implants in areas of mandible or posterior maxilla (premolars and/or molars);

  • bacterial plaque index ≤ 20% (Silness & Loe, 1964);

  • bleeding rate of ≤ 20% (Loe & Silness, 1963);

  • Sufficient alveolar bone volume for an implant of:

  • Length: 8 or 10mm

  • Diameter: 3.5mm, 4. 00mm or 4. 5mm

  • Bone quality type I-III;

  • No associated bone regeneration.

Exclusion Criteria:
  • Pregnant and lactating women;

  • Uncontrolled diabetes;

  • History of chemotherapy or radiotherapy in the last 5 years;

  • Radiotherapy in areas of the head and neck;

  • Use of immunosuppressants, bisphosphonate or prolonged use of corticosteroids;

  • Smokers;

  • Alcohol or drug abuse;

  • Untreated periodontitis;

  • History of previous bone increase in the implant installation region;

  • Presence of residual roots at the site receiving the implant;

  • Bone density type IV

  • Individuals with connective tissue disorders or metabolic diseases;

  • Postmenopausal osteoporosis or other systemic diseases that may affect bone metabolism;

  • Need for guided bone regeneration at the time of implant installation.

Contacts and Locations

Locations

Site City State Country Postal Code
1 School of Dentistry - University of São Paulo São Paulo Brazil 05508-900

Sponsors and Collaborators

  • University of Sao Paulo
  • Plenum (M3 Health Industria e Comercio de Produtos Médicos)

Investigators

  • Principal Investigator: Giuseppe A Romito, PhD, University of São Paulo, Brazil

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Giuseppe Alexandre Romito, Professor, University of Sao Paulo
ClinicalTrials.gov Identifier:
NCT05627037
Other Study ID Numbers:
  • 59844422.4.0000.0075
First Posted:
Nov 25, 2022
Last Update Posted:
Nov 25, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Giuseppe Alexandre Romito, Professor, University of Sao Paulo

Study Results

No Results Posted as of Nov 25, 2022